Coronavirus / COVID

Booster doses of the Pfizer-BioNTech COVID-19 vaccine were shown to provide greater protection against infection than the 2 dose primary regimen alone, according to a study of health care workers in Israel.

Gilead’s remdesivir was granted expanded FDA approval to treat non-hospitalized adult and adolescent patients at high risk of severe or fatal COVID-19 disease progression.

A third dose of the Pfizer-BioNTech or AstraZeneca mRNA COVID-19 vaccines produced sufficient neutralizing antibody titers against the Omicron variant.

Former members of the Biden transition team recommend accepting that the virus is here to stay.

Donald Alcendor, PhD, and Angela Rasmussen, PhD, explain how to discuss the importance of COVID-19 booster shots with patients.

Jeff Goad, PharmD, MPH, and Angela Rasmussen, PhD review the population trends of COVID-19 booster shots.

The CDC reported that post-infection immunity paired with COVID-19 vaccination was very protective against the Delta variant.

“Memory” CD4+ and CD8+ T cells may explain why Omicron causes less severe disease than previous COVID-19 variants.

For already-vulnerable cancer patients, a COVID-19 diagnosis is especially concerning. A new study reveals that when it comes to disease outcomes, geographical location is not a factor—but individual cancer centers can make a difference.

As global health leaders discuss the best long-term strategy for COVID-19 vaccines and boosters, consensus is emerging that repeated boosters of current vaccines within short intervals is not sustainable.

An Israeli study is the first to administer 4 COVID-19 shots, but the boosted antibodies may still not be enough to prevent Omicron breakthrough infections.

Eliminating the NS2 viral protein of Respiratory Syncytial Virus (RSV) helps the body to destroy the virus before it causes severe inflammation.

Study finds high false positive results with one batch of a rapid antigen test for SARS-CoV-2 but "very low" overall false positive rate.

A study adds to the growing list of trials assessing convalescent plasma in COVID-19 to yield mixed results.

People who vape with e-cigarettes and contract COVID-19 are significantly more likely to experience symptoms.

Telemedicine, virtual health consultations, may help increase access to care among under-resourced demographics during the COVID-19 pandemic.

An explanation of the risks associated with COVID-19 booster shots.

Dr Peter Salgo leads a discussion on the safety and efficacy of COVID-19 booster shots with a comparison to historical vaccine rollouts.

Key signs and symptoms to help distinguish between the 2 respiratory illnesses.

Even if they did not experience severe symptoms, unvaccinated people who contract COVID-19 while pregnant are more likely to have poor birth outcomes.

Over 1 in 10 people may harbor infectious and transmissible COVID-19 virus after the recommended 10-day quarantine period.

COVID-19-infected people experiencing incarceration or homelessness in the US had higher rates of hospitalization and readmission than the general population.

Shortages of health care workers and an increase in COVID-19 cases has put a severe strain on the health care system. Thus, the opportunity to reduce the hospitalizations for other conditions and expand outpatient treatment opportunities should be welcomed.

A model simulated the efficacy of the US’s COVID-19 vaccine rollout, measuring its correlation with reduced hospitalizations and deaths.

No influenza-related hospitalizations of children were found in a nationwide study of the impact of the COVID-19 pandemic on the 20/21 flu season.

During a continuation of a difficult time in our history, overwhelmed providers need to take a step back and find time for themselves to unwind and destress from COVID-19.

A study of children positive for COVID-19 found the overall risk of developing severe disease to be low, but risk factors included age, underlying chronic illness, and symptom duration.

Heterologous vaccine intervention (HVI), receiving immune-boosting vaccinations other than a COVID-19 shot, may alleviate COVID-19 case burdens.

Pfizer CEO Albert Bourla made the announcement in an interview.

The award given to the research institute by the state of Pennsylvania looks to delve deep in understanding vulnerable populations and taking some lessons away in addressing future potential pandemics.